Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Drug-drug interaction study of NS-580 in healthy male subjects
jRCT2071220031Phase 1Completed
- Sponsor
- Nippon Shinyaku
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of friluglanstat, sponsored by Nippon Shinyaku. Primary endpoint: Primary PK parameters of NS-580 and combination drugs. Started Aug 2022; status: completed.
02
Drugs
friluglanstat
Beyond the preview
Go deeper on jRCT2071220031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220031.